慢性肾脏病合并房颤与卒中:SGLT2i、非甾体MRA和GLP-1 RA时代及高竞争性死亡风险下的风险评分
房颤与慢性肾脏病常共存,共享危险因素和病理生理,导致卒中、出血、心衰和早死负担高。CHA₂DS₂-VASc和HAS-BLED评分推导人群晚期CKD患者少,可能未充分涵盖CKD特异性血栓栓塞和出血风险修饰因素。该观点文章批判性评估传统风险评分,强调现代预防治疗和竞争性死亡背景下的局限,并提出更动态、以肾脏为中心的风险分层优先方向。
要点
- CHA₂DS₂-VASc和HAS-BLED在晚期CKD患者中推导不足,可能低估CKD特异性风险。
- 高CHA₂DS₂-VASc评分可能间接识别竞争性死亡风险更高的患者。
- RAAS阻断、MRA、SGLT2i和GLP-1 RA广泛使用改变心肾预后,挑战历史评分校准。
核心结论
- 传统房颤风险评分在CKD患者中因推导人群限制和现代治疗影响而校准不足。
- 需要更动态、以肾脏为中心的风险分层工具来整合CKD特异性修饰因素和竞争性死亡风险。
研究设计与样本
- 观点文章,批判性评估CKD合并房颤患者中传统卒中与出血风险评分。
主要发现
- CHA₂DS₂-VASc和HAS-BLED推导人群包含晚期CKD患者相对少,可能未充分涵盖CKD特异性风险修饰因素。
- 高CHA₂DS₂-VASc评分可能间接识别竞争性死亡风险更高的患者。
- RAAS阻断、MRA、SGLT2i和GLP-1 RA的广泛使用重塑心肾预后,进一步挑战历史评分校准。
临床怎么用
- 临床应认识到传统评分在CKD患者中的局限性,不应仅依赖评分进行抗凝决策。
- 需关注竞争性死亡风险对卒中风险评估的影响,并考虑现代心肾保护治疗对预后的改变。
局限性
- 为观点文章,未提供新的原始数据或验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atrial fibrillation (AF) and chronic kidney disease (CKD) frequently coexist, share risk factors and pathophysiology, and confer a high burden of stroke, bleeding, heart failure, and premature death. Risk scores such as CHA₂DS₂-VASc, which estimates thromboembolic risk, and HAS-BLED, which estimates bleeding risk, were derived in populations including relatively few patients with advanced CKD. Consequently, they may not adequately account for CKD-specific modifiers of thromboembolic and hemorrhagic risk. Although these scores do not formally incorporate competing non-stroke mortality, higher CHA₂DS₂-VASc scores may indirectly identify patients with a greater competing risk of death. Meanwhile, widespread use of renin-angiotensin-aldosterone system blockade, mineralocorticoid receptor antagonists, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide‑1 receptor agonists has reshaped cardiorenal prognosis, further challenging historical calibrations of stroke and bleeding scores. In this perspective, we critically appraise conventional risk scores in AF with CKD, highlight their limitations in the context of modern preventive therapies and competing mortality, and outline priorities for more dynamic, kidney‑focused risk stratification.
引用
- Zoccali C, Kovesdy C, Mallamaci F, et al. Chronic kidney disease, atrial fibrillation, and stroke: risk scores in the era of SGLT2i, non-steroidal MRA, and GLP-1 RA, and presence of high competing mortality. Nephrol Dial Transplant. 2026. PMID: 42622348. doi:10.1093/ndt/gfag191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。